Allergan PLC McGhan Croissant-Shaped Tissue Expanders, Style 134 Product Usage: intended for temporary subcutaneous implantation and require periodic, incremental inflation with sterile saline for injection until the desired amount of tissue is developed. Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
McGhan Croissant-Shaped Tissue Expanders, Style 134 Product Usage: intended for temporary subcutaneous implantation and require periodic, incremental inflation with sterile saline for injection until the desired amount of tissue is developed.
Brand
Allergan PLC
Lot Codes / Batch Numbers
ALL LOTS
Products Sold
ALL LOTS;
Allergan PLC is recalling McGhan Croissant-Shaped Tissue Expanders, Style 134 Product Usage: intended for temporary subcut due to The action was initiated following notification by the U.S. FDA of their recently updated, global safety information concerning the higher incidence o. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
The action was initiated following notification by the U.S. FDA of their recently updated, global safety information concerning the higher incidence of anaplastic large cell lymphoma (BIA-ALCL) in patients who have textured breast implants.
Recommended Action
Per FDA guidance
UPDATE: On June 1, 2020, Allergan issued a press release outlining a dedicated multi-channel campaign to contact women who may not be aware of the Biocell recall and to improve tracking information for U. S. Breast Implant patients (link: https://news.abbvie.com/news/press-releases/allergan-aesthetics-launches-dedicated-multi-channel-campaign-to-contact-patients-who-may-not-be-aware-biocell-recall-and-to-improve-tracking-information-for-us-breast-implant-patients.htm) On July 24, 2019, Allergan issued a press release related to the recall was posted on the Allergan website (Allergan.com). Recall letters were sent on August 6, 2019 via: FedEx overnight mail with tracking to all consignees who may have product within expiry. The recall letter will inform customers to do the following: 1. If you have inventory of the recalled products, Quarantine product to prevent its use. 2. Conduct a physical count of the affected products in your possession and record the count on the enclosed Recall Stock Response Form. 3. Send the Recall Stock Response Form to Inmar Rx Solutions, Inc via fax or email within five (5) business days of receipt. To ensure we are able to account for all recalled product, it is imperative that you return the form. 4. Upon receipt of the Response Form, Inmar will issue Return Authorization label(s). 5. When returning the recalled products, attach the prepaid FedEx Authorized Return shipping label to the outside of the return carton and return the recalled product to: Inmar Rx Solutions, Inc. 4332 Empire Rd. Fort Worth, TX 76155 6. Please Do Not return any products that are not the subject of this recall. Please contact Inmar Rx Solutions, Inc. if you have any questions about these recall actions. Patient letters were mailed on August 14, 19 and 26, 2019 to all impacted patients to which Allergan had complete names and addresses in their device tracking database. The patient letters informed customers of the following: 1. How
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026